Detailed profiling of anti-desmoglein autoantibodies identifies anti-Dsg1 reactivity as a key driver of disease activity and clinical expression in pemphigus vulgaris

被引:20
|
作者
Naseer, S. Y. [1 ]
Seiffert-Sinha, K. [1 ]
Sinha, A. A. [1 ]
机构
[1] SUNY Buffalo, Dept Dermatol, Buffalo, NY 14203 USA
关键词
Age at onset; disease phase; disease duration; lesion morphology; Immunoprofiling; LINKED-IMMUNOSORBENT-ASSAY; PHENOTYPE; ELISA; ANTIBODIES; REMISSION; SEVERITY;
D O I
10.3109/08916934.2014.976629
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
With their near-universal presence in patients and ease of clinical measurement, anti-desmoglein (Dsg) antibodies serve as primary candidates for creating prognostic tools in Pemphigus vulgaris (PV). Although the desmoglein compensation hypothesis postulates a clear relationship between anti-Dsg autoantibodies and clinical phenotype in PV, recent studies have questioned the fidelity of this hypothesis as a predictor of lesion morphology. Moreover, few studies address the association of anti-Dsg antibodies to other clinical parameters such as disease phase and age at onset. Using the largest patient repository to date in PV, we present a detailed analysis of anti-desmoglein antibody profiles across a comprehensive range of dynamic (disease phase, therapy, lesion morphology) and temporal (disease duration, age at sampling, age at onset) clinical parameters. Our data highlight the non-traditional but key role of anti-Dsg1 levels in tracking disease activity. We show that declining anti-Dsg1 levels may predict progression from active phase to early remission and long-term maintenance of remission, regardless of lesion morphology. In contrast, many remittent patients have elevated levels of anti-Dsg3 without lesional activity. Furthermore, we describe a unique subset of remittent patients that develop chronic transient lesions (lasting <1 week) in the setting of elevated anti-Dsg3 levels but do not meet the consensus criteria for active phase. Re-classification of patients with transient lesions as "active'' may shed new light on pathophysiological processes underlying cycles of blister formation and rapid spontaneous healing in PV. Additionally, we provide evidence for the potential attenuation of the immune response with prolonged disease duration. Our data fit into the broader effort of immunoprofiling to promote data-informed decision-making regarding diagnosis, prognosis and treatment of complex diseases.
引用
收藏
页码:231 / 241
页数:11
相关论文
共 12 条
  • [1] The anti-desmoglein 1 autoantibodies in pemphigus vulgaris sera are pathogenic
    Ding, X
    Diaz, LA
    Fairley, JA
    Giudice, GJ
    Liu, Z
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1999, 112 (05) : 739 - 743
  • [2] The pathogenic activity of anti-desmoglein autoantibodies parallels disease severity in rituximab-treated patients with pemphigus vulgaris
    Sinistro, Anna
    Calabresi, Valentina
    Lupi, Francesca
    Sera, Francesco
    Frezzolini, Alessandra
    Ruffelli, Marina
    De Pita, Ornella
    Camaioni, Diana
    Cianchini, Giuseppe
    Di Zenzo, Giovanni
    EUROPEAN JOURNAL OF DERMATOLOGY, 2015, 25 (06) : 578 - 585
  • [3] The pathogenic activity of anti-desmoglein autoantibodies parallels disease severity in rituximab-treated patients with pemphigus vulgaris
    Anna Sinistro
    Valentina Calabresi
    Francesca Lupi
    Francesco Sera
    Alessandra Frezzolini
    Marina Ruffelli
    Ornella De Pità
    Diana Camaioni
    Giuseppe Cianchini
    Giovanni Di Zenzo
    European Journal of Dermatology, 2015, 25 : 578 - 585
  • [4] Anti-desmoglein 1 and-3 profiles as predictors of disease variation in pemphigus vulgaris
    Naseer, S. Y.
    Seiffert-Sinha, K.
    Sinha, A. A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2014, 134 : S10 - S10
  • [5] Avidity of anti-desmoglein antibodies in patients with pemphigus vulgaris (PV) and pemphigus foliaceus (PF) does not correlate with disease activity or clinical improvement
    Hassan, K. M.
    Streilein, R. D.
    Hall, R. P.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2007, 127 : S16 - S16
  • [6] Longitudinal Tracking of Autoantibody Levels in a Pemphigus Vulgaris Patient: Support for a Role of Anti-Desmoglein 1 Autoantibodies as Predictors of Disease Progression
    Abidi, Nadia Y.
    Lainiotis, Irene
    Malikowski, Gretchen
    Seiffert-Sinha, Kristina
    Sinha, Animesh A.
    JOURNAL OF DRUGS IN DERMATOLOGY, 2017, 16 (02) : 135 - 139
  • [7] Correlation between salivary and serum anti-desmoglein 1 and 3 antibody titres using ELISA and between anti-desmoglein levels and disease severity in pemphigus vulgaris
    De, D.
    Khullar, G.
    Handa, S.
    Joshi, N.
    Saikia, B.
    Minz, R. W.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2017, 42 (06) : 648 - 650
  • [8] Correlation of anti-γ/ε nicotinic acetylcholine receptor antibody levels with anti-desmoglein 1,3 antibody levels and disease severity in pemphigus vulgaris
    Toosi, R.
    Teymourzadeh, A.
    Mahmoudi, H.
    Balighi, K.
    Daneshpazhooh, M.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2021, 46 (07) : 1230 - 1235
  • [9] Anti-desmoglein 3 autoantibodies cloned from the IgA1 repertoire of an IgA pemphigus patient are directly pathogenic, but not sufficient for disease induction
    Emtenani, S.
    Johns, J.
    Langenhan, J.
    Komorowski, L.
    Hundt, J. E.
    Schmidt, E.
    Zillikens, D.
    Ludwig, R. J.
    Hammers, C. M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (10) : S256 - S256
  • [10] Salivary and Serum Anti-Desmoglein 1 and 3 ELISA and Indirect Immunofluorescence in Pemphigus Vulgaris: Correlations with Serum ELISA, Indirect Immunofluorescence and Disease Severity
    Koopaie, Maryam
    Mortazavi, Hossein
    Khatami, Alireza
    Khodashenas, Zohreh
    ACTA DERMATOVENEROLOGICA CROATICA, 2018, 26 (02) : 91 - 99